Clinical Trial Update: Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating equivalence of Estradiol vaginal cream 0.01% to Estrace® Cream 0.01% in atrophic vaginitis has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrophic Vaginitis

Drugs mentioned

• Estrace® Cream 0.01% (estrace cream 0.01%)
• Estradiol vaginal cream 0.01% (estradiol vaginal cream 0.01%)

Snippet

Sponsor: Actavis Inc. | Conditions: Atrophic Vaginitis | Phase 3 | Status: COMPLETED | Results posted: 2019-12-26